RESUMEN
Objective:To investigate the effect of ANF, PRA, AT-? and ALD on the occurrence of Heart failure patients and Congestive heart failure(CHF) .Methods:The plasma were measured by radioimmunoassay(RIA) in 163 patients(112 on heart failure patients,51 congestive heart failure)before and after taking Angiotensiin converting enzyme. The results were as foron: ll. Results:The concentrations of ANF, PRA,AT-? and ALD in acute myocardid infarction, Rheumatic valvuar disease, cor pulmonale and Hypertension patients were higher significantly than the contorl group(heart failure)( P 0.05) .After taking ACE inhibitor,AT an extent, the values were decreased-ANF 32.5%, AT-? 25.3 % and ALD 27.1 % , A positive correlation was shown between ANF system and RSSA system. Conclusion: The results suggested that monitoring of ANF,PRA,AT-? and AID with RIA technique showed a beneficial to heart's disease and heart's dysfunction.
RESUMEN
Se propuso revisar los nuevos conocimientos sobre los receptores de la angiotensina II y las implicaciones clínicas y terapéuticas derivadas de su bloqueo farmacológico. Se destacó la reconocida importancia del sistema renina-angiotensina en la regulación cardiovascular y renal y se explicó que sus efectos están medidos por la acción de la AII sobre sus receptores (tipo 1 y tipo 2). Se concluyó que los recientes avances en el control farmacológico de ese sistema, especialmente por la aparición de nuevos antagonistas de los receptores de la AII activos por vía oral, como el losartán, pueden ser de extraordinaria eficacia en el tratamiento de la hipertensión arterial, insuficiencia cardíaca y en evitar la progresión de la insuficiencia renal crónica.
The purpose of this paper was to review the new knowledge about angiotensin II receptors as well as the clinical and therapeutic implications resulting from their pharmacological block. It was stressed the great importance of the renin-angiotensin system in the cardiovascular and renal regulation and it was also explained that its effects are measured by the action of AII on its receptors (type 1 and type 2). It was concluded that the recent advances achieved in the pharmacological control of that system, specially due to the appearance of new orally active angiotensin II receptor antagonists, such as losartan, may be extraordinarily efficient in the treatment of arterial hypertension and heart failure, and may prevent the progression of chronic kidney failure.